Our history and achievements
The early years
Arthritis Research UK began life as the Empire Rheumatism Council, set up in 1936 by Dr Will Copeman, an eminent physician and Fellow of the Royal College of Physicians (RCP), and other like-minded doctors, who were committed to stopping the pain of arthritis.
World War II intervened, but crucially, in 1950, the speciality of rheumatology was recognised by the RCP – a sign that musculoskeletal conditions as we know them today were being taken seriously by the medical profession.
In 1953 the charity set up the UK’s first Chair of Rheumatology at the University of Manchester. The following year we founded the university’s now renowned epidemiology unit to better understand the causes and development of disease.
In the 1950s, the charity began to train doctors and medical students and educate the public. The first information booklet, on rheumatoid arthritis, was published in 1956; osteoarthritis followed two years later.
From the 1960s onwards our research began to show that arthritis is neither simply a wear and tear condition, nor an inevitable part of ageing.
Arthritis Research UK’s flagship research centre, the Kennedy Institute, was responsible for the charity’s biggest success yet. Scientists Tiny Maini and Marc Feldmann research into the activities of a disease-causing molecule called tumour necrosis factor (TNF) in the 1990s. This led to a whole new class of drugs called anti-TNF therapy, transforming the lives of people with rheumatoid and other types of inflammatory arthritis over the past 15 years.
In more recent years we have undertaken big genome screens to find the genes that cause osteoarthritis, lupus and ankylosing spondylitis. We have invested in research to help the millions of people living with osteoarthritis, previously a hugely underfunded area of research, despite causing pain and disability to eight million people in the UK.
Our network of experimental treatment centres have supported the testing and development of new treatment for arthritis and related conditions.
We're funding the first clinical trial in the UK to compare different cell types in the treatment of osteoarthritis. The aim is to repair damage to the joint, stop the condition getting worse and delay, or even avoid, the need for knee replacement surgery.
Another exciting development is the use of targeted treatments. Instead of treating all patients with a particular type of arthritis in the same way, the treatment they receive is personalised based on the way the patient experiences their condition and how this affects their response to treatment. This could help the thousands of people with rheumatoid arthritis for whom current drug therapies don’t work.
We've worked also hard to ensure key decision makers in government at all levels take arthritis more seriously, and make it a priority. Our reports have helped to improve government policy relating to people with arthritis in the healthcare and public health systems. In 2014 this campaigning spirit went further still, to a call for candidates in the 2015 general election to champion the prevention and cure of arthritis, and transforming the services for people with the condition by becoming an Arthritis Champion.
At Arthritis Research UK, we invest in breakthrough treatments, the best information and vital support for everyone affected by arthritis. We believe that by harnessing the power of exceptional science we can overcome the pain, isolation and fatigue arthritis causes, making everyday life better for all the 10 million people in the UK.